HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

Top Cited Papers
Publisher Website
Google Scholar
Abstract
Insights into antibody therapy for HIV-1: Despite the success of antiretroviral therapy, HIV-1-infected individuals still harbor latent virus. Thus, other therapeutic strategies are needed. A single injection of a broad and potent monoclonal antibody targeting the HIV-1 envelope protein reduced viral loads in HIV-1-infected individuals, albeit only transiently. Lu et al. now report that antibody treatment not only blocked free virus from infecting new cells, it also accelerated the clearance of infected cells. Furthermore, Schoofs et al. demonstrate that therapeutic antibody treatment enhanced infected individuals' humoral response against the virus. Thus, neutralizing antibodies may be a promising therapy for HIV-1 because of their potential to reduce the viral reservoir. Science , this issue pp. 1001 and 997
Funding Information
  • Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (OPP1032144, OPP1092074, OPP1124068)
  • Robertson Foundation
  • NIH Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (1UM1 AI100663-01, 1UM1 AI00645)
  • University of Pennsylvania Center for AIDS Research Single Genome Amplification Service Center P30 (AI045008)
  • NIH (UM1AI068618, UM1AI069481, F30 AI112426, HIVRAD P01 AI100148)
  • Deutsche Forschungsgemeinschaft (SCHO 1612/1-1, KL 2389/2-1)
  • European Research Council (ERC-StG639961)
  • German Center for Infection Research
  • German National Academic Foundation
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (248676/2013-0)